Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
A first-in-human, unblinded, phase I trial of Paclitaxel-loaded tumor penetrating
microparticles (TPM) in peritoneal carcinomatosis patients who are not eligible for
standard-of-care therapeutic interventions.
Phase:
Phase 1
Details
Lead Sponsor:
Carlos Chan
Collaborator:
Institute of Quantitative Systems Pharmacology (IQSP)